Welcome to our dedicated page for X4 Pharmaceuticals SEC filings (Ticker: XFOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. X4 is a biopharmaceutical issuer focused on rare hematology diseases and rare diseases of the immune system, and its filings offer detailed insight into how it reports on the development and commercialization of mavorixafor (marketed in the U.S. as XOLREMDI® in its first indication), its chronic neutropenia clinical programs, and its capital structure.
Through Forms 10‑K and 10‑Q, X4 outlines its business description, risk factors, financial condition, and progress in advancing CXCR4‑targeted therapies. Current reports on Form 8‑K, several of which are summarized in the materials provided, disclose material events such as private placements of common stock and pre‑funded warrants, an underwritten public offering, an equity purchase agreement with Lincoln Park Capital Fund, LLC, strategic restructuring actions including a workforce reduction, and changes in executive and board leadership. These filings also reference press releases that contain financial results, trial updates, and other corporate developments.
Investors interested in X4’s clinical and regulatory trajectory can use the filings to follow disclosures related to the global, pivotal Phase 3 4WARD trial in chronic neutropenia, Phase 2 data presentations, and the company’s description of chronic neutropenia and the CXCR4/CXCL12 axis. Proxy and compensation‑related documents, when filed, provide additional detail on governance and executive arrangements, while Forms 4 and related ownership filings (when available) show reportable insider transactions in XFOR stock.
Stock Titan enhances these documents with AI‑powered summaries that highlight key points from lengthy filings, including major financing terms, restructuring details, and clinical program references. Real‑time updates from EDGAR ensure that new X4 Pharmaceuticals filings, from quarterly reports to 8‑Ks describing material agreements, appear promptly, allowing users to quickly understand how regulatory disclosures relate to the company’s rare hematology and CXCR4‑focused strategy.
X4 Pharmaceuticals, Inc. ownership update: Morgan Stanley, Morgan Stanley Investment Management Inc., and Inception Trust report substantial beneficial ownership of Common Stock.
The filing shows Morgan Stanley reporting units hold 8,884,338 shares with shared voting and dispositive power (reported 10.2% of the class). Morgan Stanley Investment Management Inc. is reported with 8,884,304 shares (10.2%) and Inception Trust with 4,518,236 shares (5.2%). Signatories include authorized representatives for the three filers, dated 03/06/2026.
X4 Pharmaceuticals, Inc. received an amended Schedule 13G/A from Biotechnology Value Fund–affiliated entities and Mark N. Lampert reporting a significant but sub‑5% passive stake. As of December 31, 2025, the group may be deemed to beneficially own 3,411,993 common shares, or about 3.9% of the company.
The position includes Pre-Funded Common Stock Purchase Warrants exercisable for 1,178,251 shares, with a token exercise price of $0.001 per share and no expiry, subject to a 9.99% ownership cap. The filers certify the securities are not held to change or influence control of X4 Pharmaceuticals.
Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, and Ortav Yehudai report beneficial ownership of 5,227,222 shares of X4 Pharmaceuticals common stock as of December 31, 2025, representing 5.8% of the company.
The position includes 2,571,478 shares held directly and 2,655,744 shares underlying prefunded warrants, all held through Trails Edge Biotechnology. The ownership percentage is based on 87,436,688 shares outstanding as of October 31, 2025. The filers certify the holdings are not for the purpose of changing or influencing control of X4 Pharmaceuticals.
X4 Pharmaceuticals, Inc. disclosed that a group of Bain Capital Life Sciences funds and related entities collectively reported beneficial ownership of 8.41% of its common stock as of December 31, 2025. This total includes 615,649 common shares, a pre-funded warrant for up to 7,047,216 shares, and additional warrants for up to 304,589 shares.
The warrants and pre-funded warrants are subject to Beneficial Ownership Blockers
Saturn V Capital Management LP and Xiaoying Tian report beneficial ownership of 6,433,481 shares of X4 Pharmaceuticals, Inc. common stock, representing 7.36% of the class. The percentage is based on 87,436,688 shares outstanding as of October 31, 2025.
The shares are held across pooled investment vehicles and managed accounts (the “Clients”) for which Saturn V serves as investment manager. Saturn V and Ms. Tian have shared voting and dispositive power over all 6,433,481 shares, with no sole voting or dispositive power.
No individual Client holds or beneficially owns five percent or more of X4’s outstanding shares, and both Saturn V and Ms. Tian expressly disclaim beneficial ownership of the shares held by the Clients. The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of X4 Pharmaceuticals.
X4 Pharmaceuticals received an updated ownership report from Nantahala Capital Management and its principals. As of December 31, 2025, the reporting group may be deemed to beneficially own 2,449,468 shares of common stock, representing 2.80% of the outstanding shares.
The filing shows that Nantahala, Wilmot B. Harkey, and Daniel Mack share voting and dispositive power over these shares through funds and separately managed accounts. They certify the holdings are kept in the ordinary course of business and are not intended to change or influence control of X4 Pharmaceuticals.
Morgan Stanley and its investment management arm have reported a significant passive stake in X4 Pharmaceuticals, Inc. They beneficially own 8,196,489 shares of X4 common stock, representing 9.4% of the outstanding class as of December 31, 2025.
The filing shows no sole voting or dispositive power; all 8,196,489 shares are held with shared voting and shared dispositive power. The firms certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of X4 Pharmaceuticals.
FMR LLC and Abigail P. Johnson report a significant passive ownership stake in X4 Pharmaceuticals, Inc. common stock on an amended Schedule 13G. They beneficially own 8,499,100 shares, representing 9.7% of the outstanding common stock, with sole dispositive power over all reported shares.
The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of X4 Pharmaceuticals, or in connection with any control-related transaction.
Empery Asset Management, LP and Ryan M. Lane report a significant stake in X4 Pharmaceuticals, Inc. They beneficially own 9,043,894 shares of X4 Pharmaceuticals common stock as of December 31, 2025, including 92,789 shares issuable upon exercise of warrants, representing 9.99% of the outstanding common stock.
This percentage is calculated using 90,436,688 shares outstanding, which includes 87,436,688 shares reported as of October 31, 2025 plus 3,000,000 shares issued from warrant exercises completed by December 31, 2025. The warrants are subject to a 9.99% “Blocker” that prevents the reporting persons from exercising warrants if it would push their ownership above 9.99% of the company’s outstanding common stock.
Empery Asset Management acts as investment manager to the funds that hold the shares and warrants, and Lane is the individual who ultimately oversees the investment manager. They certify that the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of X4 Pharmaceuticals.
X4 Pharmaceuticals director Bridger Gary received a new stock option grant. On 01/01/2026, he was awarded options to purchase 110,000 shares of X4 Pharmaceuticals common stock at an exercise price of $4.00 per share, expiring on 01/01/2036.
The options will vest in full only if stockholders approve an increase in the share reserve under the company’s Amended and Restated 2017 Equity Incentive Plan at the company’s 2026 annual meeting of stockholders, and if he continues providing services through that date. This filing reports an equity-based compensation grant rather than a share sale.